The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle
and Co., Chicago, IL) for the management of non-viable first trimester pregnancies.
Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant
management in who have documented non-viable gestations. We will examine the following
outcome variables: time to resolution, number of patients requiring dilation and curettage,
change in hematocrit, cost to the institution, patient satisfaction, and reported side
effects.